Hi Hilge. Could you elaborate on your comment further please? Do you mean that efti's good results have already been - or are likely to be - eclipsed by those of Enhertu? If so, what value (clinical or otherwise) do you see in progressing further with efti in an immuno-oncology setting? Surely efti might also have a valuable role in the treatment & cure of several cancers, assuming continued favourable data? Or should we be prepared to turn our company's attention to developing cures for autoimmune diseases with IMP761?
Hi Hilge. Could you elaborate on your comment further please? Do...
-
- There are more pages in this discussion • 268 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
0.015(4.92%) |
Mkt cap ! $464.8M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 32.5¢ | 30.0¢ | $1.168M | 3.702M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 148547 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 51809 | 2 |
View Market Depth
| Last trade - 16.10pm 24/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |